Valuation: ALTEOGEN Inc.

Capitalization 20,998B 14.59B 13.89B 13.1B 11.57B 20.67B 1,264B 22.94B 156B 57.79B 529B 54.7B 53.6B 2,219B P/E ratio 2024 *
905x
P/E ratio 2025 * 889x
Enterprise value 20.95B 14.56M 13.86M 13.07M 11.54M 20.62M 1.26B 22.89M 156M 57.65M 527M 54.57M 53.47M 2.21B EV / Sales 2024 *
248x
EV / Sales 2025 * 192x
Free-Float
72.75%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
Alteogen to Raise KRW155 Billion via Stock Sale Feb. 04 MT
Alteogen Enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous Enhertu Enabled by Alteogen's Hybrozyme Technology Nov. 10 CI
Alteogen Inc. Receives Ministry of Food and Drug Safety Approval for Tergase® 24-07-08 CI
Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA 23-09-05 CI
ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 23-05-15 CI
ALTEOGEN Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 23-03-20 CI
ALTEOGEN Inc. Enters into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by its Hybrozyme Technology 23-01-02 CI
Alteogen Inc. Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients 21-03-08 CI
Alteogen Enters Into Exclusive License Agreement With Intas to Develop and Commercialize Two Products Enabled by Its Hybrozyme™ Technology 21-01-07 CI
ALTEOGEN Inc. announced that it has received KRW 74.999925 billion in funding from SG Core Co., Ltd. 21-01-06 CI
ALTEOGEN Inc. announced that it expects to receive KRW 74.999925 billion in funding from SG Core Co., Ltd. 20-12-13 CI
ALTEOGEN Inc. announced that it has received KRW 29.9992875 billion in funding from Shinhan Bank, SL Investment, Future Growth Strategy Bio New Technology Investment Fund, Korea Investment Holdings Co., Ltd., Korea Securities Finance Corporation 20-11-11 CI
ALTEOGEN Inc. announced that it expects to receive KRW 29.9992875 billion in funding from Shinhan Bank, SL Investment, Future Growth Strategy Bio New Technology Investment Fund, Korea Investment Holdings Co., Ltd., Korea Securities Finance Corporation 20-11-03 CI
More news
1 day-1.85%
1 week-5.48%
Current month-0.27%
1 month+23.91%
3 months-12.10%
6 months+26.67%
Current year+19.71%
More quotes
1 week
366 000.00
Extreme 366000
400 000.00
1 month
302 500.00
Extreme 302500
400 000.00
Current year
298 000.00
Extreme 298000
400 000.00
1 year
84 100.00
Extreme 84100
455 500.00
3 years
27 875.00
Extreme 27875
455 500.00
5 years
15 305.56
Extreme 15305.5556
455 500.00
10 years
3 590.28
Extreme 3590.2778
455 500.00
More quotes
Director TitleAgeSince
Chief Executive Officer 70 2008-05-12
Director of Finance/CFO 59 2020-05-31
Chief Tech/Sci/R&D Officer 59 -
Manager TitleAgeSince
Chairman 70 2008-05-12
Director/Board Member 59 2020-05-31
Director/Board Member 60 2021-03-28
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-1.85%-5.48%+327.83%+820.50% 14.59B
+1.14%-4.80%-8.31%+5.48% 79.12B
+1.90%+17.90%+40.69%+56.37% 58.36B
-3.58%-4.65%+91.85%+112.44% 35.96B
-0.81%-2.84%-37.79%-35.86% 20.1B
+0.59%-5.00%+21.64%+6.66% 13.63B
-0.19%+0.64%+77.55%+141.17% 13.58B
+0.67%+1.44%-24.60%-27.95% 12.36B
+4.31%+0.99%+9.19%-32.53% 11.95B
-4.39%-3.61%+23.56%+63.70% 9.94B
Average -0.22%-2.09%+52.16%+111.00% 26.96B
Weighted average by Cap. +0.19%-2.39%+38.70%+77.61%
See all sector performances

Financials

2024 *2025 *
Net sales 84.5B 58.72M 55.9M 52.72M 46.56M 83.19M 5.09B 92.31M 628M 233M 2.13B 220M 216M 8.93B 109B 75.67M 72.04M 67.94M 60.01M 107M 6.56B 119M 809M 300M 2.74B 284M 278M 11.51B
Net income 23B 15.98M 15.21M 14.35M 12.67M 22.64M 1.38B 25.13M 171M 63.3M 579M 59.91M 58.71M 2.43B 23.55B 16.36M 15.58M 14.69M 12.98M 23.19M 1.42B 25.73M 175M 64.82M 593M 61.34M 60.11M 2.49B
Net Debt -50.2B -34.88M -33.21M -31.32M -27.66M -49.42M -3.02B -54.84M -373M -138M -1.26B -131M -128M -5.3B -71.6B -49.75M -47.36M -44.67M -39.46M -70.49M -4.31B -78.22M -532M -197M -1.8B -187M -183M -7.57B
More financial data * Estimated data
Logo ALTEOGEN Inc.
Alteogen Inc. is a Korea-based company mainly engaged in the research and development of biopharmaceuticals. The Company operates biobetter business segment, which develops protein pharmaceuticals and cancer therapies, and bio similar business segment, which develops bio similar and animal medicines. The Company mainly provides growth hormone, herceptin, humira, antibodies, animal drugs and others.
Employees
145
More about the company
Date Price Change Volume
25-02-14 394,000.00 +6.34% 788,705
25-02-13 370,500.00 -1.85% 517,401
25-02-12 377,500.00 -0.13% 486,787
25-02-11 378,000.00 -3.57% 621,324
25-02-10 392,000.00 +0.13% 475,080

End-of-day quote Korea S.E., February 12, 2025

More quotes
Trading Rating
Investor Rating
ESG MSCI
CCC
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
394,000.00KRW
Average target price
565,000.00KRW
Spread / Average Target
+43.40%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A196170 Stock